US companies Sequenom Laboratories and Recombine have launched a new HerediT Universal carrier screening test, which offers comprehensive genetic information.

With the launch of HerediT, which offers comprehensive genetic information, Sequenom Laboratories expands its reach into the universal carrier screening market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sequenom president William Welch said: "Carrier screening remains an important part of genetic risk assessment and is now being utilised by physicians for patients planning families."

The HerediT Universal test is capable of screening more than 250 genetic diseases by analysing more than 2,000 genetic mutations.

"The test can be performed preconception or at any time during pregnancy, while current options are limited to single gene testing or tests that can identify 100 hereditary conditions."

New York University Fertility Centre programme director James Grifo said: "Though individually rare, genetic disorders are collectively common and are a significant cause of childhood mortality.

See Also:

"An expanded carrier screening test provides an opportunity to look beyond a patient’s family history or ethnic predispositions to particular diseases, which is increasingly valuable as the obstetrics and gynaecology (OB/GYN) physician community incorporates broader screening into its routine standard of care."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the test can be performed preconception or at any time during pregnancy, while current options are limited to single gene testing or tests that can identify 100 hereditary conditions.

Recombine CEO Alex Bisignano said: "We are excited to collaborate with Sequenom Laboratories, the market leader in non-invasive prenatal testing, to bring this expanded carrier screening technology to the OB/GYN and maternal foetal medicine space.

"This strategic alliance will help us reach more patients, and enable them to use comprehensive genetic testing and counselling services to make informed decisions in family planning."

With a focus principally on prenatal care, Sequenom Laboratories developed a broad range of laboratory tests under the brand names HerediT, MaterniT21 PLUS, SensiGene and VisibiliT.

These tests offer early patient management information for obstetricians, geneticists, and maternal foetal medicine specialists.